BRGX (BioRegenx) Cyclically Adjusted PS Ratio: (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BioRegenx Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioRegenx  (OTCPK:BRGX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


BioRegenx Cyclically Adjusted PS Ratio Related Terms


BioRegenx Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for BioRegenx's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioRegenx Cyclically Adjusted PS Ratio Chart

BioRegenx Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.35 0.00

BioRegenx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.00 0.69 0.00 0.00

BRGX vs VYND, ACON, MGRX: Cyclically Adjusted PS Ratio Comparison

For the Health Information Services subindustry, BioRegenx's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioRegenx Cyclically Adjusted PS Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, BioRegenx's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioRegenx's Cyclically Adjusted PS Ratio falls into.



BioRegenx Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

BioRegenx's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, BioRegenx's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

BioRegenx Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200106 0.000 178.000 0.000
200109 0.000 178.300 0.000
200112 0.000 176.700 0.000
200203 0.000 178.800 0.000
200206 0.000 179.900 0.000
200209 0.000 181.000 0.000
200212 0.000 180.900 0.000
200303 0.000 184.200 0.000
200306 0.000 183.700 0.000
200309 0.000 185.200 0.000
200312 0.000 184.300 0.000
200403 0.000 187.400 0.000
200406 0.000 189.700 0.000
200409 0.000 189.900 0.000
200412 0.000 190.300 0.000
200503 0.000 193.300 0.000
200506 0.000 194.500 0.000
200509 0.031 198.800 0.051
202012 0.000 260.474 0.000
202103 0.000 264.877 0.000
202106 0.000 271.696 0.000
202109 0.000 274.310 0.000
202112 0.000 278.802 0.000
202203 0.000 287.504 0.000
202206 0.000 296.311 0.000
202209 0.000 296.808 0.000
202212 0.000 296.797 0.000
202303 0.002 301.836 0.002
202306 0.001 305.109 0.001
202309 0.001 307.789 0.001
202312 0.001 306.746 0.001
202403 0.001 312.332 0.001
202406 0.001 314.175 0.001
202409 0.001 315.301 0.001
202412 0.001 315.605 0.001
202503 0.001 319.799 0.001
202506 0.000 322.561 0.000
202509 0.001 324.800 0.001
202512 0.000 324.054 0.000
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioRegenx Business Description

Address 7407 Ziegler Road, Chattanooga, TN, USA, 37421
BioRegenx Inc develops and manufactures medical test equipment and high-quality, science-based nutritional products. The Company distributes wellness devices. The products are sold nationally through a direct selling channel to health professionals and research organizations. The company operates and manages its business as one reportable and operating segment as a medical testing, diagnostic and nutraceutical company. It focuses on commercialization of its patented technologies in its field.